Isabelle Vuissoz

photo de Isabelle Vuissoz


Professor - Teacher / Researcher
HDR
Equipe 2 Groupe 3
Laboratoire INSERM 1256 NGERE Campus Brabois Santé Bât. C 2 ème étage9 avenue de la Forêt de Haye – BP 2019954505 Vandoeuvre-lès-Nancy Cedex – France
isabelle.grillier-vuissoz@univ-lorraine.fr
isabelle-grillier-vuissoz
LinkedIn GoogleScholar Orcid

My research aims to identify new therapeutic targets in aggressive cancers. After initially working on nuclear receptor signaling, I shifted my focus to claudins, particularly claudin-1, investigating its role in cell migration, adhesion, and sensitivity to chemotherapy in triple-negative breast cancer. I am now extending this work to other claudins, notably in glioblastoma, and I also contribute to a project on inflammatory bowel diseases (IBD), focusing on cell junctions, the role of claudins, and epithelial barrier integrity.

Keywords: nuclear receptors, thiazolidinediones (TZDs), claudins, apoptosis, cell migration, cell junctions, chemosensitivity, triple-negative breast cancer (TNBC), glioblastoma.

Administrative responsibilities
Head of the first-year Master’s programme (M1) in Cellular Biology and Physiology, Master’s Degree in Life Sciences, and member of the Master’s programme steering committee.
Member of the Science and Technology Collegium, Université de Lorraine.

Main teaching
Cell Biology at Bachelor’s and Master’s levels, preparation for the CAPES examination in Life and Earth Sciences, and History of Biology (first-year Bachelor’s level).

PhD in Life and Health Sciences (University of Lille, 1994) and holder of an Habilitation to Supervise Research (HDR) entitled “Nuclear Receptors and Cancer” (Henri Poincaré University, 2010), I am Professor of Cell Biology at the University of Lorraine and a researcher at the N-GERE laboratory (Inserm U1256). Following a postdoctoral fellowship at UCLA focused on leukemia, and subsequent research at the University of Lausanne on PPAR nuclear receptors, I developed several research lines in oncology, notably on estrogen signaling, thiazolidinediones, and claudins in breast cancer. My current research focuses on claudins as potential biomarkers and therapeutic targets, particularly in glioblastoma. I also contribute to research on inflammatory bowel diseases, with a focus on cell junctions, epithelial barrier integrity, and the development of intestinal organoid models.